Tissue repairResearch Market

Cartalax

A synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, studied for cartilage-protective and geroprotective effects in preclinical models.

CartilageJoint HealthBioregulatorKhavinson

Also referenced as: AED, Ala-Glu-Asp

Also appears in: Longevity

Price compare
50 tracked offers across 50 vendors · 14 dosages
Best trust-adjusted value: Peptide Crafters · Moderate trust · $1.49/mg
From
$1.49/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$1.65/mg
Market median$2.75/mg
Current coverage27 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Cartalax crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence74 certificate records mentioning this compound or product name29 provider-linked · 61 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Tissue-repair research

Primary research area: Tissue repair. Also surfaces under Longevity for browsing and discovery.

Aliases
2

AED, Ala-Glu-Asp

Signal depth
Medium

No FDA label signal · 287 trials · 8107 PubMed results

Promising
Research evidence

Cartalax has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Cartalax has 7 name-matched clinical trials (highest phase: Phase 3) and 8108 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data
Phase 3
Trial quality
Large RCT
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
High-impact
PHASE3 · RandomizedCognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)PHASE1 · RandomizedAED/Statin Interaction StudyNA · RandomizedSmartCPR Trial: An Analysis of a Waveform-Based Automated External Defibrillation (AED) Algorithm on Survival From Out-of-Hospital Ventricular FibrillationResuscitation · 255 citationsLocal lay rescuers with AEDs, alerted by text messages, contribute to early defibrillation in a Dutch out-of-hospital cardiac arrest dispatch systemArchives of Neurology · 229 citationsThe AED (Antiepileptic Drug) Pregnancy RegistryResuscitation · 216 citationsOptimal refresher training intervals for AED and CPR skills: A randomised controlled trial
Evidence history
  1. 2026-08-25Preclinical→PromisingBand Preclinical → Promising; +8 trials; +1 PubMed
  2. 2026-08-22Promising→PreclinicalBand Promising → Preclinical; -2 trials; +1 PubMed
  3. 2026-08-18Preclinical→PromisingBand Preclinical → Promising; +12 trials
  4. 2026-08-15Promising→PreclinicalBand Promising → Preclinical; -12 trials; +2 PubMed
  5. 2026-08-14Preclinical→PromisingBand Preclinical → Promising; +12 trials; +2 PubMed
  6. 2026-08-13Promising→PreclinicalBand Promising → Preclinical; -9 trials; +1 PubMed
  7. 2026-08-05Preclinical→PromisingBand Preclinical → Promising; +6 trials; +1 PubMed
  8. 2026-08-01Promising→PreclinicalBand Promising → Preclinical; -6 trials; +1 PubMed
  9. 2026-07-09PromisingFirst graded

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Cartalax?

Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp (AED), developed as part of Vladimir Khavinson’s bioregulator peptide program at the Saint Petersburg Institute of Bioregulation and Gerontology. It is classified as a cartilage-tissue bioregulator and is often discussed alongside other Khavinson peptides like Epitalon, Pinealon, and Thymalin.

How it works

The proposed mechanism follows the Khavinson bioregulation model:

  • Peptide-DNA interaction — short peptides are theorized to penetrate cell nuclei and modulate gene expression in a tissue-specific manner (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Cartilage matrix support — Cartalax is proposed to regulate genes involved in proteoglycan and collagen synthesis in chondrocytes, though the specific gene targets have not been identified in Western literature
  • Geroprotective effects — in rodent aging studies, combinations of short bioregulatory peptides (including AED-containing preparations) have been associated with improved tissue function in aged animals (Khavinson, Gerontology, 2005)

Research status

  • Khavinson (2005) reviewed 35 years of bioregulator peptide research including cartilage-targeted peptides (Gerontology, 51(2):70–75)
  • Khavinson & Malinin (2005) described the theoretical basis for tissue-specific short peptide bioregulation (Neuroendocrinology Letters, 26(3):233–238)
  • Anisimov et al. (2003) showed life extension in rodents treated with bioregulator peptide preparations (Annals of the New York Academy of Sciences, 992:141–147)

The evidence base is primarily Russian-language publications from the Khavinson group. No independent Western replication studies or human clinical trials have been published.

Key considerations

  • Part of a family of Khavinson bioregulators commonly sold together (Cartalax + Pinealon + Epitalon combinations)
  • Research originates from a single group with limited independent replication
  • Often combined with BPC-157 and TB-500 by vendors in recovery-oriented blends
  • Available as lyophilized powder or capsules from research vendors